207940.KS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 02:30):

Stats
Today's Volume	80 548.00
Average Volume	70 183.00
Market Cap	54 803.98B
EPS	KRW0 ( 2024-04-24 )
Next earnings date	( KRW2 823.26 ) 2024-07-24
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW973.73 (0.13%)

Volume Correlation

Long: -0.38 (neutral)

Short: -0.79 (moderate negative)

Signal:(42.352) Neutral

Samsung Biologics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Samsung Biologics Correlation - Currency/Commodity

-0.13
( neutral )

0.11
( neutral )

0.53
( weak )

-0.12
( neutral )

-0.31
( neutral )

-0.73
( moderate negative )

Samsung Biologics Financials

Annual	2023
Revenue:	KRW3 694.59B
Gross Profit:	KRW1 802.76B (48.79 %)
EPS:	KRW12 050

FY	2023
Revenue:	KRW3 694.59B
Gross Profit:	KRW1 802.76B (48.79 %)
EPS:	KRW12 050

FY	2022
Revenue:	KRW3 001.30B
Gross Profit:	KRW1 468.45B (48.93 %)
EPS:	KRW11 442

FY	2021
Revenue:	KRW1 568.01B
Gross Profit:	KRW726.45B (46.33 %)
EPS:	KRW5 948.61

Financial Reports:

No articles found.

Samsung Biologics

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.